Moreover, our results suggest that the combination therapy of Ad-SGE-REIC and bevacizumab exhibits anti-glioma effects by upregulating the ER stress pathway, downregulating the Wnt signaling pathway, and suppressing the angiogenesis and invasion of tumor cells. This evidence concerns the gene DKK3 and glioma.